Drug Developement/Delivery
- PROTAC Degraders in Clinical Trails: 2026 Update
- Bispecific Antibodies - Current Status and Prospects
- PROTAC Vepdegestrant Approved: PROTAC Linker Design & PEG Linkers
- Beyond GLP-1 - Novel Targets for Weight Loss
- Next-Generation PDC: Linker Design with PEG & Clinical Progress
- Oral Macrocyclic Peptides in Clinical Practice
- FDA 2025 Approvals: Innovation and Next-Gen Blockbuster Drugs
- 2026 FDA Drug Approvals: Blockbusters to Watch
- The Rise of PD-L1 ADCs: A New Paradigm in Cancer Therapy
- Peptide Lipidation: A Breakthrough Strategy
